Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
Primary Care
How do you approach treating alopecia secondary to endocrine therapy?
Other causes have been ruled out. Any role for spironolactone?
Related Questions
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
Is there any definitive contraindication to use tamoxifen in patients with a brain aneurysm that is being monitored?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
